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Case report
Clinical presentation of exclusive cystic fibrosis
lung disease
Inez Bronsveld, Jan Bijman, Frauke Mekus, Manfred Ballmann, Henk J Veeze,
Burkhard Tümmler
Abstract
The diagnosis of cystic fibrosis (CF) is
based on the occurrence of two mutations
in the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene and on
assays that measure the basic defect of
abnormal chloride transport in the af-
fected organs. However, in cases of atypi-
cal CF not all diagnostic tests may be
positive. We present a patient with an
atypical CF phenotype in whom the only
presenting symptom was severe CF-like
lung disease substantiated by an abnormal
nasal potential diVerence. Genetic analy-
sis showed that the patient was a sympto-
matic heterozygote, which suggests that
one lesion in the CFTR gene may be suY-
cient to cause CF-like lung disease.
(Thorax 1999;54:278–281)
Keywords: cystic fibrosis; atypical cystic fibrosis; nasal
potential diVerence; genetics
Typical cystic fibrosis (CF) is caused by two
lesions in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene which
give rise to a generalised exocrine disease of the
respiratory, gastrointestinal, reproductive, and
hepatobiliary tracts.1 The protein product of
the CFTR gene is a chloride channel expressed
in the apical membrane of epithelial cells2 so
diagnostic tests that measure the chloride con-
ductance in exocrine epithelia—for example,
the pilocarpine iontophoresis sweat test,3 intes-
tinal current measurement (ICM),4 and nasal
potential diVerence (NPD)5 6—have abnormal
values in cases of typical CF. Atypical cases of
CF have a diVerent clinical presentation with
pancreatic suYciency, mild bronchitis, nasal
polyposis, congenital bilateral absence of the
vas deferens (CBAVD), a borderline sweat test,
or ICM values which point to low residual
chloride secretion in intestinal tissue either by
CFTR or an alternative chloride channel.7–10
We present a case characterised exclusively by
severe lung disease in whom other organs typi-
cally involved in CF were not aVected and who
failed to show a defect in chloride transport.
Patient history
The 34 year old patient was the third child of
Caucasian first generation cousins. The first
child was born preterm with meconium ileus
and died at day 10. The second child died dur-
ing infancy at six months and CF was
suspected at necropsy. Our patient suVered
from chronic nasal polyposis which had led to
13 polypectomies between the age of five and
23 years. By the age of 15 years she was referred
to a chest physician because of shortness of
breath during sports activity. Clubbing, sub-
normal lung function, and decreased exercise
tolerance were noted. The diagnosis of CF was
proposed because of the typical pulmonary
manifestations but was discarded when normal
sweat electrolyte concentrations were found.
The diVerential diagnosis of allergy as the
underlying disease was excluded by normal IgE
skin prick tests and normal serum levels of spe-
cific IgE. Immotile cilia syndrome was ex-
cluded by the normal microscopic appearance
of biopsy specimens of nasal cilia. Since
adolescence she had been underweight (below
3rd percentile) and had recurrent lower airway
infections. Over the years increased sputum
production and chronic cough became a clini-
cal problem. A lung biopsy specimen in 1984
showed a histological pattern consistent with
CF (bronchiectasis with localised purulent
bronchitis and surrounding fibrosis). Cultures
of throat swabs or sputum were often positive
for Staphylococcus aureus (>90% of samples)
but never for Pseudomonas aeruginosa. How-
ever, the specific anti-P aeruginosa oprF IgG
titre was positive, indicating that she had been
exposed to P aeruginosa. Bronchodilators and
intermittent antibiotics were prescribed but the
patient generally discontinued medication after
a few days, even during acute respiratory tract
infections. At the age of 23 her lung function
was reduced (vital capacity 1.5 l (48% pre-
dicted)), her chest radiograph had a Chrispin-
Norman score of 20, grade 3 (range 0–38), her
height was at the 25th percentile and weight
below the 3rd percentile. However, her pancre-
atic function was suYcient as shown by normal
chymotrypsin levels in 1986, 1992, 1995, nor-
mal stool elastase levels (386 mg/g) in 1995,
and by ultrasound investigation of the pan-
creas. She had never received pancreatic
enzymes or vitamin supplements. Serum levels
of vitamins (vitamin A 370 µg/l, vitamin E
11 mg/l), bilirubin and liver enzymes were
always in the normal range. Moreover, in
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repetitive pilocarpine iontophoresis sweat tests
performed since she was 11 years old the sweat
electrolyte levels were always normal (range
7–32 mEq/l).
Methods
This study was approved by the medical ethical
committees of the Dutch and German partici-
pating hospitals and informed consent was
obtained from the patient. All chemicals were
obtained from the Sigma Chemical Co, St
Louis, Missouri, USA.
ANALYSIS OF THE CFTR GENE
The promoter (–3.8 to –0.3 kb) and coding
regions and the exon flanking intron sequences
of the CFTR gene were screened for mutations
by single strand conformation polymorphism
(SSCP) analysis11 12 and, in the case of the
appearance of non-wild type band patterns in
the high resolution SSCP gel, by subsequent
sequencing.13 Deletions in the CFTR gene were
sought by repeated Southern hybridisations of
macrorestriction blots with CFTR cDNA
probes encoding exon 1, exons 7–24, or the sec-
ond nucleotide binding fold (codons 1202–
1422). Preparation of unsheared genomic DNA
from fresh blood, complete restriction digestions
with ApaI, EagI, FspI, SalI or XhoI, pulsed field
gel electrophoresis, blotting and hybridisation
followed protocols 1, 5, 7, 8 and 9 of Bautsch et
al.14 The intragenic CFTR haplotype was deter-
mined for the sequence alterations T854T and
M470V,15 16 the splice site polymorphism in
intron 8 (TG)mTn,
11 17 and the microsatellites
IVS8CA, IVS17bCA, IVS17bTA.18 19
NASAL POTENTIAL DIFFERENCE (NPD)
NPD was measured using an adaptation of the
method described previously.5 In short, the nasal
turbinate was superfused (1.7 ml/min) for peri-
ods of three minutes with the following solutions
(mol/l): saline to measure baseline PD; amilo-
ride (10–4) to block Na+ channels; gluconate with
amiloride to assess spontaneous Cl– conduct-
ance; isoprenaline (10–4) in gluconate with ami-
loride to evaluate the presence of CFTR, and
ATP (10–3) in isoprenaline/gluconate+amiloride
solution to open non-CFTR Cl– channels. To
access the submucosal space a small needle (25
gauge) was inserted into the forearm and filled
with saline. Both the needle and superfusion
catheter were connected to a high input
resistance voltage measuring device via salt
bridges and Ag/AgCl electrodes. The saline
solution consisted of (mmol/l): NaCl (120), Na
gluconate (25), K gluconate (5), NaH2PO4
(0.4), Na2HPO4 (2.4). In the gluconate solution
NaCl was replaced by Na gluconate (145). All
solutions were adjusted to pH 7.4.
INTESTINAL CURRENT MEASUREMENT (ICM)
The method used to study ICM has been
described previously.4 Freshly obtained rectal
biopsy specimens were mounted in saline solu-
tion in the Ussing chamber (aperture 1.2 mm).
After stabilising the basal short circuit current
(Isc) the tissue was exposed to the following
inhibitors and secretagogues (mol/l) to the
mucosal (M) or serosal (S) side: glucose (10–2,
M+S); amiloride (10–4, M); indomethacin
(10–5, M+S) to inhibit basal Cl– secretion by
inhibiting the endogenous prostaglandin for-
mation; carbachol (10–4, S), a Ca2+ linked
secretagogue; forskolin (10–5, M+S) + 8-bromo
cyclic adenosine monophosphate (cAMP, 10–3,
M+S) to open Cl– channels by activation of a
cAMP-dependent protein kinase and phospho-
rylation of specific membrane proteins; 4,4'-
diisothiocyanatostilbene-2,2'-disulphonic acid
(DIDS, 2.10–4, M) to inhibit Ca2+ dependent
Cl– secretion; and histamine (5.10–4, S) to reac-
tivate the Ca2+ activated pathway.
Results
CFTR GENETICS
Despite the familial consanguinity, the patient
was heterozygous at the CFTR locus which is
shown by the diVerent number of (TA)n repeats
(n = 30, 34) for the microsatellite at the locus
IVS17bTA and her heterozygosity for a rare
CFTR mutation. She was homozygous
(TG)12T7-2-1 for the CFTR haplotype
(TG)mTn-M470V-T854T. The combination of
the TG12 repeat with the T7 allele and the V470
CFTR isoform are known to decrease signifi-
cantly the amount and chloride channel activ-
ity of CFTR.16 After all CFTR exons and flank-
ing intron sequences and most of the promoter
Figure 1 Autoradiogram of genomic ApaI digestions
probed with CFTR cDNA (exon 7–24). No anomalous
band pattern is seen for the sample from the patient (lane
1). For comparison, lane 4 shows the probe reactive
fragments from a specimen which carries a deletion in one
CFTR allele. ApaI cleaved fragments were separated in a
CHEF-DRTMII cell at 5.6 V/cm in 1% agarose gels (0.5
TBE buVer, 10°C). Pulse times were linearly increased in
two ramps from 5 to 20 s in 18 hours and from 5 to 90 s in
20 hours.
Table 1 Electrophysiological results for the study patient. Mean (SD) values for a control
group and a group of patients with CF are given for comparison
Control
group
Study
patient CF group
Nasal potential diVerence (mV) n = 25 n = 23
baseline and ÄPD after addition of:
baseline −24 (11) −52 −45 (10)
amiloride +10 (6) +21 +21 (9)
Cl– free solution −15 (10) −3 −1 (5)
isoprenaline −8 (4) −4 −2 (3)
ATP −1 (3) 0 −1 (3)
Intestinal current measurement (µA/cm2) n = 50 n = 51
ÄIsc after addition of:
amiloride −8.7 (11) −4.9 −8.7 (11)
carbachol 38.5 (23) 45.5 −5.3 (10)
histamine (after DIDS incubation) 33.0 (26) 19.4 −5.0 (10)
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area up to –4 kb had been screened by SSCP,
one molecular lesion (the splice site consensus
transition 1898+3 A->G) was identified. A
pancreatic insuYcient child with CF at our
clinic is homozygous for this condition and
exhibited the typical pulmonary and gastro-
intestinal manifestations of CF indicating that
1898+3 A->G is a CF-causing lesion. No
anomalous bands were seen in autoradiograms
of macrorestriction blots probed with CFTR
cDNAs, indicating that the two CFTR alleles of
our patient do not carry any major genomic
alteration (fig 1).
DIAGNOSTIC ASSESSMENT
On the day of electrophysiological investigation
at the age of 32 she was underweight (below the
3rd percentile with a body mass index of
17 kg/m2) and her lung function was severely
reduced (FEV1 0.39 l (14% predicted), FVC
1.23 l (38% predicted)). At this time she was
treated with continuous oxygen and showed
severe clubbing. Electrophysiological measure-
ments were carried out by assessing the
presence of chloride conductance in her airway
and intestinal epithelium (table 1). The basal
NPD was –52 mV (fig 2). In the presence of
amiloride the PD depolarised to –31 mV, a
decrease of 40%. Superfusion of gluconate in
the presence of amiloride resulted in a net
response of –3 mV, indicating subnormal Cl–
conductance. With isoprenaline, which opens
CFTR Cl– channels, only a small response of
–4 mV was obtained which suggested that few
CFTR channels are present. No ATP response,
which is usually indicative of the presence of
alternative Cl– channels,20 was seen in the
airway tissue.
In previous ICM studies carbachol has pro-
voked a negative reversed Isc in rectal tissue of
patients with CF, sometimes followed by a
positive residual response indicating the pres-
ence of residual Cl– secretion. In our patient the
ICM showed a Cl– secretory current in the
normal range on addition of carbachol (fig 3).
DIDS, which inhibits the alternative pathway
of Ca2+ activated Cl– currents, did not influence
the Cl– current, suggesting the presence of nor-
mal CFTR mediated chloride conductance in
the intestine.
Discussion
The clinical and diagnostic features presented
by this case are conflicting in terms of the
expression of the basic defect in diVerent
tissues. In typical CF defective electrolyte
transport in the sweat gland, intestinal and air-
way epithelium is shown by a pathological out-
come of the sweat test, ICM and NPD. In our
case, however, the sweat chloride concentration
and ion flow in the intestine were normal while
the NPD values were abnormally high. Patho-
logically raised NPD values have so far only
been found in CF and not in any other lung
disease with related clinical manifestations
such as á1-antitrypsin deficiency, immotile cilia
syndrome, or congenital bronchiectasis.21 As
well as a high baseline nasal PD, the patient’s
gluconate and isoprenaline response were also
in the CF range. However, they do point to the
presence of little residual CFTR Cl– permeabil-
ity in her respiratory epithelium. The clinical
symptoms of our patient, such as progressive
obstructive bronchitis and bronchiectasis, spu-
tum production, and pathological bacterial
flora, are typical of CF and she has been
permanently on oxygen since the age of 30.
This could explain her anorexic status since
there is no sign of malabsorption or gastro-
intestinal disease, as confirmed by normal vita-
min A and E levels, pancreatic suYciency, and
a normal ICM. This highly discordant expres-
sion of the basic defect in diVerent tissues is
described here for the first time: CFTR
function was unaVected in gastrointestinal tis-
sue whereas in airway tissue the abnormally
low Cl– conductance can only be accounted for
by defective epithelial Cl– transport. Other
cases of CF with normal sweat test results and
pulmonary disease, as described for patients
carrying the A455E or 3849+10 kb C->T
mutation,7 8 22 23 can clearly be diagnosed by an
abnormal ICM even when there are few or no
clinical signs of gastrointestinal involvement.10
The CFTR gene was screened for disease
causing lesions in all exons and flanking intron
sequences and on one chromosome a sequence
alteration in a donor splice site was found
Figure 2 Nasal potential diVerence (PD) measurements
of the patient (x) and mean (SD) PD values of 25 controls
(L) and 23 patients with CF (Ä) following superfusion
with saline solution, amiloride (10–4 M) in saline solution,
Cl– free solution with amiloride, isoprenaline (10–4 M) in
Cl– free solution with amiloride, and ATP (10–3 M) in Cl–
free solution with amiloride and isoprenaline.
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Figure 3 Measurements of intestinal current expressed as
changes in short circuit current (Isc) of the patient (x) and
mean (SD) Isc of 50 controls (L) and 51 patients with CF
(Ä) following the addition of amiloride, carbachol, and
exposure to 4,4'-diisothiocyanatostilbene-2,2'-disulphonic
acid (DIDS) + histamine.
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(1898+3 A->G). This sequence alteration was
first described in a compound heterozygous
pancreatic suYcient patient (Ferrari et al, per-
sonal communication) and was found also in a
pancreatic insuYcient CF patient homozygous
for this condition (see above). According to
CFTR mutation analysis and the family anam-
nesis, our patient is a carrier for one CFTR
mutation and hence should not express any CF
symptoms. However, she carries an unfavour-
able combination of common intragenic poly-
morphisms. She is homozygous TG12T7 for the
TGmTn polymorphism at the intron 8 splice
acceptor site, and the TG12 repeat together with
the T7 stretch places the branch point nucle-
otide in an unfavourable position for splicing
leading to 30% of exon 9− CFTR transcript
which are known to be translated in CFTR
proteins that do not mature.16 24 Moreover, she
is homozygous for the V470 allele in exon 10.
V470 CFTR proteins have a 1.7 fold decreased
intrinsic chloride channel activity compared
with M470 CFTR proteins.16 These predispos-
ing polymorphisms in the intragenic back-
ground decrease the expression and function of
CFTR. Yet, they are present in both rectal and
nasal tissue and cannot account for the
unimpaired function of CFTR in the intestine
while in the nasal tissue almost complete
absence of Cl– conductance was found. How-
ever, the patient’s consanguineous descent
leads to a genome-wide overrepresentation of
homozygous genotypes which may lead to fur-
ther unfavourable combinations of factors that
modify CFTR expression or lung function. As
gastrointestinal disease is not present, we
propose that the genetic background predis-
poses to severe lung disease caused by tissue
specific regulatory elements which lead to the
loss of CFTR function exclusively in the respi-
ratory epithelium.
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schaft.
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